{"id":"W4391693695","doi":"10.1136/bmjgast-2023-001218","title":"Determining the optimal treatment target in patients with ulcerative colitis: rationale, design, protocol and interim analysis for the randomised controlled VERDICT trial","year":2024,"lang":"en","type":"article","venue":"BMJ Open Gastroenterology","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":38,"is_retracted":false,"has_abstract":true,"ca_institutions":"Barrie Urology Group; University of Calgary; Western University","funders":"Allergan; Genentech; European Crohn's and Colitis Organisation; Celltrion; Wellcome Trust; Celgene; Janssen Pharmaceuticals; Gilead Sciences; Sanofi; Takeda Pharmaceuticals U.S.A.; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb; Mylan; GlaxoSmithKline","keywords":"Medicine; Ulcerative colitis; Interim analysis; Internal medicine; Randomized controlled trial; Intention-to-treat analysis; Verdict; Vedolizumab; Endoscopy; Observational study; Surgery; Gastroenterology; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.07652819,0.004787491,0.007706583,0.00215985,0.00187604,0.004059796,0.002872069,0.006974415,0.02852793],"category_scores_gemma":[0.08018079,0.002681662,0.006136684,0.002898094,0.00366703,0.002250643,0.002133533,0.006317363,0.006662207],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003079741,"about_ca_system_score_gemma":0.01076009,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007526414,"about_ca_topic_score_gemma":0.001143306,"domain_scores_codex":[0.9230319,0.0623274,0.005526891,0.003065951,0.003631715,0.002416239],"domain_scores_gemma":[0.9764102,0.009624578,0.004266791,0.004453527,0.003145567,0.002099434],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8434097,0.005859044,0.002481694,0.03209155,0.005456224,0.0003897451,0.0006484706,0.004919273,0.001809415,0.01574965,0.02893577,0.05824944],"study_design_scores_gemma":[0.8854782,0.02913318,0.003235159,0.007842593,0.003786675,0.0002170405,0.0001569606,0.005900975,0.001291395,0.01139632,0.05134939,0.0002121938],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"protocol","genre_gemma":"protocol","genre_scores_codex":[0.004262855,0.001135185,0.008834245,0.0008834383,0.001109724,0.9795877,0.00212435,0.0001555491,0.001907035],"genre_scores_gemma":[0.004336627,0.0001937278,0.007634607,0.000395561,0.00009050928,0.9866974,0.0003234565,0.00001250387,0.0003156528],"genre_candidate":"protocol","genre_consensus":"protocol","teacher_disagreement_score":0.07652819,"threshold_uncertainty_score":0.4047246,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0243157338020686,"score_gpt":0.3257400812305416,"score_spread":0.301424347428473,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}